Federal Register / Vol. 86, No. 141 / Tuesday, July 27, 2021 / Notices 40211 

EARLY TERMINATION GRANTED

[07/21/2021] 

20211736 ........ G Green Dot Corporation; Republic Bancorp, Inc.; Republic Bank & Trust Company. 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division, Department of Justice. 

[FR Doc. 2021–15904 Filed 7–26–21; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–866] 

Importer of Controlled Substances 

Application: Catalent Pharma 

Solutions, LLC. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Catalent Pharma Solutions, 

LLC. has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 26, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 26, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for a hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on June 2, 2021, Catalent 

Pharma Solutions, LLC., 3031 Red Lion 

Road, Philadelphia, Pennsylvania 

19114, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric Acid .... 2010 I 

Lysergic Acid Diethylamide ...... 7315 I 

The company plans to import the 

above controlled substances as finished 

dosage unit products for clinical trials, 

research, and analytical activities. No 

other activity for these drug codes is 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–15919 Filed 7–26–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–867] 

Bulk Manufacturer of Controlled 

Substances Application: Novitium 

Pharma, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Novitium Pharma, LLC has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before September 27, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before September 27, 2021. 

ADDRESS: Written comments should be 

sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on June 17, 2021, 

Novitium Pharma, LLC., 70 Lake Drive, 

East Windsor, New Jersey 08520, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Psilocybin .................................. 7347 I 

Psilocyn ..................................... 7348 I 

The company plans to bulk 

manufacture the above controlled 

substances to produce Active 

Pharmaceutical Ingredient (API) and 

finished dosage forms for clinical trial 

purposes. No other activities for these 

drug codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–15920 Filed 7–26–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree Under the Clean Water 

Act 

On July 16, 2021, the U.S. Department 

of Justice (DOJ) lodged a proposed 

Amendment to Consent Decree with the 

United States District Court for the 

Northern District of Indiana in United 

States and State of Indiana v. City of 

Elkhart, Indiana, Civil Action No. 

2:11CV328. The lodging of the proposed 

Amendment to Consent Decree, by the 

United States on behalf of the U.S. 

Environmental Protection Agency, with 

the concurrence of the State of Indiana 

on behalf of the Indiana Department of 

Environmental Management, modifies 

the Consent Decree in this action that 

was entered by the Court on November 

30, 2011. 

The 2011 Consent Decree resolved 

claims for civil penalties as well as 

injunctive relief in the form of a Long 

Term Control Plan (LTCP) for violations 

of the Clean Water Act and related State 

law claims in connection with the City 

of Elkhart’s operation of its municipal 

wastewater and sewer system. The 

proposed Amendment to Consent 

Decree modifies the LTCP by allowing 

the City to change the technology 


lotter on DSK11XQN23PROD with NOTICES1